AI-enabled virtual primary care
Doctronic
This profile covers Doctronic consumer consultation with optional clinical escalation. Patients choose the initial question and whether to seek further care. Commercial incentives require scrutiny, but this pass did not establish that users are forced toward paid care. Prescription-renewal deployments require separate assessment.
Checklist assessment dated October 30, 2026. Independent confirmation is incomplete. Hugo has not personally verified this service.
Agency checklist · October 30, 2026
Mixed 6 of 12 yes
Document-based draft. Independent confirmation is incomplete. Hugo has not personally verified this service.
Assessed function: Doctronic anonymous AI consultation (AI Tool), distinct from identified member records, paid clinician visits, and Utah prescription-renewal decisions.
A no can mean missing documentation or institution-dependent control; it does not by itself establish harmful behavior. These categories are not clinical safety or product-quality ratings.
- Public documents do not establish actual product behavior.
- The independent review screened rules and selected evidence; it did not replicate all twelve answers for this tool.
See all twelve answers and their evidence
| Question | Answer | Evidence / review | Source and reasoning |
|---|---|---|---|
| 1. Told it is AI | Yes | documented Not independently replicated | Doctronic is an AI model trained on medical data, not a licensed doctorSource Terms Article II also say the AI Tool 'relies on artificial-intelligence models'. |
| 2. Operator and model maker named | No | not-documented Not independently replicated | Quotation not recorded; evidence repair pending. Source Doctronic Inc. is named as operator. No model maker is named: the site describes 'more than 100 specialized AI agents' and a published study (arXiv 2507.22902) does not name the underlying LLMs. The privacy policy mentions vendors 'hosting and operating AI models' without names. |
| 3. Patient chooses to use it | Yes | documented Not independently replicated | Begin immediately without signup. Simply visit doctronic.ai and start describing your health concern.Source Free and anonymous by default. Paid telehealth is separate. |
| 4. Patient sets the task | Yes | documented Not independently replicated | You choose what information to include in Input, including health informationSource The user sets the question. The site also steers toward a $39 doctor visit. |
| 5. Patient can decline or stop | Yes | documented Not independently replicated | Begin immediately without signup. Simply visit doctronic.ai and start describing your health concern.Source Self-started tool per the Q3 source. Terms say the AI Tool is free and the paid telehealth visits are separate services with human physicians. |
| 6. Patient sees the AI output | Yes | documented Not independently replicated | If you have an account, you can view and download your AI Consult Summaries anytime from your dashboard.Source Anonymous users can export a summary during a chat. After the browser is closed, the chat is gone. |
| 7. Patient can correct or challenge | No | not-documented Not independently replicated | Quotation not recorded; evidence repair pending. Source The policy lists a conditional 'Correction' right for inaccurate personal information, not a route to contest AI output. |
| 8. Patient can get a copy | No | documented Not independently replicated | If you have an account, you can view and download your AI Consult Summaries anytime from your dashboard.Source The privacy policy also lists portability as a right that depends on where you live. |
| 9. Patient can delete | Yes | documented Not independently replicated | Delete your account, and poof, your data's gone from our systems.Source This is marketing copy. Terms say the company may delete Your Content but will keep clinical and prescription-renewal records required by law. The privacy policy also lists a deletion right and says anonymous chats vanish when the browser closes. |
| 10. Training or sale does not override patient choice | No | documented Not independently replicated | we may use de-identified information (including de-identified Input and Output) for any purpose, including to develop, train and evaluate AI modelsSource Conflict: the our-philosophy and resource-center pages say 'We never train AI on it' and 'We never sell it. We never share it.' I answered by the binding privacy policy. No opt-out is documented. The Utah renewal service has stricter terms that do not apply to the AI Tool. |
| 11. Patient can run it or take it elsewhere | No | not-documented Not independently replicated | Quotation not recorded; evidence repair pending. Source Vendor-hosted only. Terms also prohibit using output to train other AI. |
| 12. No advertising or data business | No | documented Not independently replicated | to target, deliver and measure interest-based advertisingSource The policy says tracking-technology data goes to marketing and advertising partners in a way that 'may be considered selling or sharing'. The consumer health data policy lists measurement and marketing vendors as recipients. The 'No data sold' marketing claim conflicts with this. |
Initial coding: Claude Sonnet helpers, compiled by Claude Opus 5.5 (Anthropic). Selective review and corrections: GPT-6 Astra (OpenAI). Editor: Hugo Campos. Acceptance of corrections is not product verification.
Checklist rules · Independent review and limitations · Later evidence follow-up
Earlier v1.3 assessment and control finding
Historical assessment under different rules. It does not set the current checklist zone.
Agency finding, before method v1.3
Potentially agency-expanding, with vendor-funnel and framing caveats
Legacy editorial placement, pre-method: 75
This profile has not yet been reviewed under the published method. Its finding and any number are editorial placements made before the method existed.
- Evidence
- Documentary review. Public sources only, no hands-on testing by HugoScore.
- Review status
- AI draft. No person has settled the findings.
Earlier evidence and assessment
The sections below preserve the earlier review. Its classifications and provenance are historical; the checklist above gives the current draft classification.
Earlier finding · Legacy editorial placement, pre-method: 75
Method v1.3. The control line is evidence for how the agency finding arose, not a quality score. Legacy editorial placement, pre-method: 75. Not comparable with v1.3 positions.
Potentially agency-expanding, with vendor-funnel and framing caveats
This profile covers Doctronic consumer consultation with optional clinical escalation. Patients choose the initial question and whether to seek further care. Commercial incentives require scrutiny, but this pass did not establish that users are forced toward paid care. Prescription-renewal deployments require separate assessment.
Patient agency
How this tool changes agency
Portable assessments and human review can support comparison and challenge. The source does not demonstrate that generated evidence is accurate or that a human reviewer evaluates independently.
Actual anonymous unlinkability, paid-escalation presentation, independent review mechanics, citation reliability, and renewal oversight.
Patient agency assessment
Who sets and changes the goal?
Patients can choose questions and an outside clinician. The evidence supports an offered paid pathway, not a demonstrated forced funnel. Member treatment and renewal workflows give the operator additional responsibilities and access.
What can the patient understand, question, or do?
Portable assessments and human review can support comparison and challenge. The source does not demonstrate that generated evidence is accurate or that a human reviewer evaluates independently.
Can the patient evaluate the conditions of use?
The policy offers unusually concrete rights, but headline clinical language and the AI disclaimer send different signals about reliance. Anonymous and identified use must not share one blanket privacy claim.
Text findings
Conditions of use
Published controls and their limits
The policy offers unusually concrete rights, but headline clinical language and the AI disclaimer send different signals about reliance. Anonymous and identified use must not share one blanket privacy claim.
What remains unknown?
Not tested or not established
Actual anonymous unlinkability, paid-escalation presentation, independent review mechanics, citation reliability, and renewal oversight.
Who evaluated this?
AI-assisted public-source draft
Vendor statements describe published conditions, not independently verified behavior. No clinical, security, accessibility, or legal validation is claimed. Earlier evidence remains dated in the report and history.
Sources checked
Source-specific findings and retrieval limitations are recorded in the full report.
Earlier review provenance
Criteria
CAIHL-derived HugoScore framework and September 7 qualitative review priorities. Draft v1.2 numerical anchors remain unadopted.
Reviewer
AI-assisted public-source reassessment prepared in OpenAI Codex.
AI / model
OpenAI Codex / GPT-6
Human review
Hugo Campos authorized publication of these AI-assisted draft reassessments on September 8, 2026. This does not claim comprehensive human verification of every finding.
Review date
2026-09-08
Limitations
Actual anonymous unlinkability, paid-escalation presentation, independent review mechanics, citation reliability, and renewal oversight. No live product use, patient-data upload, account creation, code audit, clinical evaluation, or independent implementation validation.
Earlier review method
Focused public-source reassessment using CAIHL: patient authority, critical capacity, and informed control. Existing evidence plus one focused primary-source pass and at most one targeted follow-up. No live product testing. Numerical scores remain provisional editorial placements, not a new calculation.
Document-based draft · Medium for published choices and rights (AI-assisted draft)